This two-day conference will bring together leading experts and frontline clinicians—including pediatric cardiologists, intensivists, cardiac surgeons, nurse practitioners, and VAD coordinators—to explore the latest advancements in pediatric heart failure management and mechanical circulatory support.
International Pediatric VAD and Heart Failure Summit 2025 Read More »
This VAD Bootcamp hosted by ACTION will be a combination hands-on and didactic training session for clinicians seeking to obtain training for Ventricular Assist Devices.
ACTION VAD Bootcamp 2025 Read More »
ACTION now has nearly 40 Harmonized Protocols!
Harmonized Protocols – Updated! Read More »
In a prospective study of 265 males with Duchenne Muscular Dystrophy, nearly 30% of those with moderate or severe heart dysfunction were not receiving full consensus-directed cardiac therapy, and most did not reach target medication doses—highlighting the need to optimize treatment strategies as cardiac disease becomes a leading cause of death in DMD.
Cardiac Medication Use in ACTION for Duchenne Muscular Dystrophy Cardiomyopathy Read More »
Through the collection and use of real-world data, the field has gained greater understanding of best practices in care of these patients, as well as improved access to devices with pediatric labeling of devices previously approved only for adults. Recent and current work across the network’s major focus areas (VAD, heart failure, muscular dystrophy, and Fontan) are highlighted.
ACTION Oral Presentation Transplant Dystrophinopathy Transplantation in Males with Dystrophinopathy: An Advanced Cardiac Therapies Improving Outcomes Network (ACTION) Dystrophinopathy Registry Analysis Emily Hayes, MD et. al. Download abstract…
30th Annual Congress of World Muscle Society – ACTION Oral Presentation Read More »
The use of VADs in pediatric restrictive and hypertrophic cardiomyopathy is rare, but this ACTION multi-center registry analysis highlights that support is feasible, particularly in children with RCM. While the majority of patients were successfully bridged to transplant, outcomes were poorer in HCM patients, especially those requiring BiVAD support.
This quarterly meeting is open to everyone — all active centers, patient & family members, and industry collaborators! Join us to hear from leadership about current projects, upcoming initiatives, and opportunities
ACTION 4 ALL – June 2025 Meeting Read More »
Let’s make 2025 our best year yet! We wrapped 2024 with the exciting announcement for the FDA expanded label of Johnson & Johnson MedTech’s Impella Support System to include treatment for certain children suffering from heart failure. Achievements like this would not be possible without the continued efforts and dedication of our ACTION centers providing care to these patients, as well as entering, cleaning, and adjudicating the data. We also continued access to the Berlin Heart Active Driver under the extended trial, and we published many new ACTION manuscripts.
The Pulse — April 2025 Read More »
Check out our One Page Summary (OPS) featuring the Impella® Left CP and the Impella® 5.5 (with SmartAssist) for providers. It serves as a quick overview of the device, including, device selection, system components, display elements, waveforms, as well as highlighting anticoagulation, power sources and potential scenarios.
Impella®– One Page Summary (OPS) Read More »
